| Literature DB >> 26625234 |
Thomas Wehler1, Beatrice Wehler2, Ingo Stehle3.
Abstract
Monoclonal antibodies against the PD-1 receptor or its ligands result in a recovery of T cell responses against tumor antigens. Nivolumab is the first antibody that has been approved in lung cancer. This mode of action is very intersting, especially because of long term responses and the moderate toxicity. © Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26625234 DOI： 10.1055/s-0041-107770
Source DB: PubMed Journal: Dtsch Med Wochenschr ISSN： 0012-0472 Impact factor: 0.628